Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Finished Goods: 2016-2018

Historic Finished Goods for Amicus Therapeutics (FOLD) over the last 2 years, with Mar 2018 value amounting to $865,000.

  • Amicus Therapeutics' Finished Goods rose 284.44% to $865,000 in Q1 2018 from the same period last year, while for Mar 2018 it was $865,000, marking a year-over-year increase of 284.44%. This contributed to the annual value of $780,000 for FY2017, which is 622.22% up from last year.
  • As of Q1 2018, Amicus Therapeutics' Finished Goods stood at $865,000, which was up 10.90% from $780,000 recorded in Q4 2017.
  • Amicus Therapeutics' 5-year Finished Goods high stood at $865,000 for Q1 2018, and its period low was $57,000 during Q2 2016.
  • Over the past 3 years, Amicus Therapeutics' median Finished Goods value was $207,500 (recorded in 2017), while the average stood at $337,500.
  • Data for Amicus Therapeutics' Finished Goods shows a peak YoY surged of 622.22% (in 2017) over the last 5 years.
  • Amicus Therapeutics' Finished Goods (Quarterly) stood at $108,000 in 2016, then skyrocketed by 622.22% to $780,000 in 2017, then soared by 284.44% to $865,000 in 2018.
  • Its Finished Goods stands at $865,000 for Q1 2018, versus $780,000 for Q4 2017 and $335,000 for Q3 2017.